Security National Bank of Sioux City Iowa IA Has $4.27 Million Holdings in AbbVie Inc. $ABBV

Security National Bank of Sioux City Iowa IA lifted its position in AbbVie Inc. (NYSE:ABBV) by 13.3% in the second quarter, HoldingsChannel.com reports. The firm owned 16,964 shares of the company’s stock after acquiring an additional 1,995 shares during the period. AbbVie comprises 1.8% of Security National Bank of Sioux City Iowa IA’s investment portfolio, making the stock its 13th largest holding. Security National Bank of Sioux City Iowa IA’s holdings in AbbVie were worth $4,269,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Burk Holdings LLC bought a new stake in AbbVie in the 2nd quarter valued at $30,000. Marquette Asset Management LLC lifted its holdings in shares of AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after acquiring an additional 48 shares during the period. Abound Financial LLC acquired a new stake in shares of AbbVie during the 4th quarter valued at about $32,000. Principia Wealth Advisory LLC boosted its position in shares of AbbVie by 38.9% during the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after acquiring an additional 44 shares in the last quarter. Finally, Merkkuri Wealth Advisors LLC bought a new stake in AbbVie in the first quarter valued at about $34,000. 70.23% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ABBV shares. BMO Capital Markets increased their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. JPMorgan Chase & Co. increased their target price on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. UBS Group raised their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Finally, Wells Fargo & Company boosted their price target on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $276.64.

AbbVie Price Performance

Shares of NYSE ABBV traded down $0.12 during midday trading on Friday, hitting $263.90. The stock had a trading volume of 8,162,526 shares, compared to its average volume of 6,587,046. The company’s 50-day simple moving average is $255.24 and its 200 day simple moving average is $231.94. The firm has a market cap of $466.26 billion, a P/E ratio of 74.55, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts expect that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced that Phase 3 CERVINO results for investigational etentamig met both primary endpoints—objective response rate and progression-free survival—in relapsed or refractory multiple myeloma. The results could strengthen AbbVie’s oncology pipeline and diversify growth beyond its immunology franchise. AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio
• Positive Sentiment: New real-world studies found that VRAYLAR improved depressive symptoms, functioning and quality of life among patients with major depressive disorder and bipolar I depression. The additional evidence may support broader adoption of the drug and reinforce AbbVie’s growth outlook in psychiatry. AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR
• Positive Sentiment: Allergan Aesthetics reported statistically significant improvements from skincare regimens and DiamondGlow treatments for people taking medical weight-loss medications, offering a potential commercial opportunity in aesthetics. Allergan Aesthetics Presents New Clinical Data
• Neutral Sentiment: AbbVie declared its regular $1.73 quarterly dividend, payable November 16 to shareholders of record October 15. The payout supports income-focused investors, although the dividend was unchanged during 2026 and therefore provides no new increase catalyst. AbbVie’s Dividend Growth Remains Solid Despite a Moderate Yield
• Negative Sentiment: Analysts caution that AbbVie’s elevated valuation reflects strong expectations for SKYRIZI, while older products are declining. Any slowdown in SKYRIZI growth could pressure future earnings and the stock’s premium multiple. What Happens To AbbVie Stock If SKYRIZI Slows Down?

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.